Last reviewed · How we verify
Atorvastatin Calcium Tablets
At a glance
| Generic name | Atorvastatin Calcium Tablets |
|---|---|
| Also known as | LIPITOR |
| Sponsor | NYU Langone Health |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Atorvastatin Therapy on Xanthoma in Alagille Syndrome (PHASE4)
- Statins Against Bushfire Smoke (PHASE4)
- Atorvastatin to Reduce Cisplatin-Induced Hearing Loss Among Individuals With Head and Neck Cancer (PHASE2)
- Evaluating Bioequivalence of a Fixed Dose Combination Versus Individual Tablets of Bempedoic Acid / Ezetimibe, and Atorvastatin (PHASE1)
- Combined Effects of Statins and Exercise on Training Sensitive Health Markers (NA)
- Women's IschemiA TRial to Reduce Events In Non-ObstRuctive CAD (PHASE4)
- Prophylactic Treatment With Atorvastatin for Episodic Migraine. (PHASE2)
- A Study Evaluating Bioequivalence of a Fixed Dose Combination Versus Individual Tablets of Bempedoic Acid, Ezetimibe, and Atorvastatin (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Atorvastatin Calcium Tablets CI brief — competitive landscape report
- Atorvastatin Calcium Tablets updates RSS · CI watch RSS
- NYU Langone Health portfolio CI